Advertisement

Topics

Teva loses $235m patent trial to GSK

08:54 EDT 22 Jun 2017 | Globes

A US court dismissed Teva's claim that GlaxoSmithKline's patent for the Coreg drug was invalid.

Original Article: Teva loses $235m patent trial to GSK

NEXT ARTICLE

More From BioPortfolio on "Teva loses $235m patent trial to GSK"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

GlaxoSmithKline
GlaxoSmithKline is the third largest pharmaceutical company in the world, based on annual sales, which reached $37,134m in 2009. Spread over 100 countries, GSK employs 96,500 people, 13,000 of which are dedicated to research and development of the the ...